The generic version of Flovent Hfa is expected to be available after 26 August, 2026. The release date considers the expiry of the last patent (US7500444*PED) on the same date and does not account for possible Para IV filings.
Flovent Hfa, containing the active ingredient fluticasone propionate, is used to regulate and manage respiratory issues.
Flovent Hfa is protected by 4 patents, with the last one (US7500444*PED) expiring on 26 August, 2026. The Flovent Hfa generic will be available after the final patent expires. Below are the details of the patents: